Quantum Biotech and BIO101 Merge

<%=company1%> (Montreal) announced that its wholly owned US subsidiary, Quantum Biotechnologies USA, and BIO101 (Carlsbad, CA) have merged. BIO101's core competencies in nucleic acid purification and molecular biology grade media fit well with Quantum's gene delivery products and molecular tools business.

Garth Cumberlidge, CEO of Quantum, commented that BIO101 gives Quantum a strong base in the United States from which it will be able to better serve its client base and develop stronger relationships with the expanding biotechnology community. The BIO101 product lines will also benefit from being marketed through the company's sales and marketing infrastructure in Europe. In addition, the BIO101 product lines are complementary to Quantum's, providing valuable additional revenues without significant increases in expenditure.

The Quantum Biotechnologies group of companies supplies viral and non-viral gene delivery and gene expression technologies for researchers in the biotechnology and biopharmaceutical industries. The company has recently launched a new line of viral vectors and will soon begin offering cGMP grade vectors and monoclonal antibody services.

For more information: Garth Cumberlidge, President and CEO, Quantum Biotechnologies Inc., 1801 de Maisonneuve West, Montreal H3H 1J9, Canada. Tel: 514-935-2200. Fax: 514-935-2964. Email: ceo@qbiogene.com.

Edited by Laura DeFrancesco